Is schizophrenia a dopamine supersensitivity psychotic reaction?
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Adolf Meyer (1866-1950) did not see schizophrenia as a discrete disorder with a specific etiology but, rather, as a reaction to a wide variety of biopsychosocial factors. He may have been right. Today, we have evidence that gene mutations, brain injury, drug use (cocaine, amphetamine, marijuana, phencyclidine, and steroids), prenatal infection and malnutrition, social isolation and marginalization, can all result in the signs and symptoms of schizophrenia. This clinical picture is generally associated with supersensitivity to dopamine, and activates dopamine neurotransmission that is usually alleviated or blocked by drugs that block dopamine D2 receptors. While the dopamine neural pathway may be a final common route to many of the clinical symptoms, the components of this pathway, such as dopamine release and number of D2 receptors, are approximately normal in schizophrenia patients who are in remission. Postmortem findings, however, reveal more dimers of D1D2 and D2D2 receptors in both human schizophrenia brains and in animal models of schizophrenia. Another finding in animal models is an elevation of high-affinity state D2High receptors, but no radioactive ligand is yet available to selectively label D2High receptors in humans. It is suggested that synaptic dopamine supersensitivity in schizophrenia is an attempt at compensation for the original damage by heightening dopamine neurotransmission pathways (preparing the organism for fight or flight). The dopamine overactivity is experienced subjectively as overstimulation, which accounts for some of the clinical symptoms, with attempts at dampening down the stimulation leading to still other symptoms. Reaction and counter-reaction may explain the symptoms of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
The Human Central Nervous System
Nieuwenhuys, R., Voogd, J., & van Huijzen, C. (2008) · doi:10.1007/978-3-540-34686-9 · Cited by 1,262
Kellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520
Human brain dopamine receptors in children and aging adults
Seeman, P., Bzowej, N. H., Guan, H. ‐., Bergeron, C., Becker, L. E., Reynolds, G. P., Bird, E. D., Riederer, P., Jellinger, K., Watanabe, S., et al. (1987) · Synapse · doi:10.1002/syn.890010503 · Cited by 404
Self-citationElevated dopa decarboxylase activity in living brain of patients with psychosis
Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., & Dyve, S. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11651 · Cited by 342
Silvestri, S., Seeman, M. V., Negrete, J.-C., Houle, S., Shammi, C. M., Remington, G. J., Kapur, S., Zipursky, R. B., Wilson, A. A., Christensen, B. K., et al. (2000) · Psychopharmacology · doi:10.1007/s002130000532 · Cited by 311
Self-citationKinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218dcd5 · Cited by 256
All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors
Seeman, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00162.x · Cited by 228
Self-citationChouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168
Tadokoro, S., Okamura, N., Sekine, Y., Kanahara, N., Hashimoto, K., & Iyo, M. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr006 · Cited by 92
Research works printed but not linked: 50
- Brébion, 2009, Hallucinations and two types of free-recall intrusion in schizophrenia, Psychol Med, 39, 917, 10.1017/S0033291708004819 · DOI
- Buchsbaum, 2006, D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia, Schizophr Res, 85, 232, 10.1016/j.schres.2006.03.042 · DOI
- Byerly, 2005, Obsessive compulsive symptoms in schizophrenia: frequency and clinical features, Schizophr Res, 76, 309, 10.1016/j.schres.2005.02.004 · DOI
- Campos, 2010, Motor behavior abnormalities in drug naive patients with schizophrenia spectrum disorders, Mov Disord, 25, 1068, 10.1002/mds.23050 · DOI
- Charuchinda, 1987, Dopamine D2 receptors in the rat brain: autoradiographic visualization using a high-affinity selective agonist ligand, J Neurosci, 7, 1352, 10.1523/JNEUROSCI.07-05-01352.1987 · DOI · Paper page
- Chouinard, 1990, Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment, Schizophr Res, 5, 21, 10.1016/0920-9964(91)90050-2 · DOI
- Chouvardas, 1996, The symbolic and literal in schizophrenic language, Perspect Psychiatr Care, 32, 20, 10.1111/j.1744-6163.1996.tb00502.x · doi:10.1111/j.1744-6163.1996.tb00502.x
- Corin, 1992, Positive withdrawal and the quest for meaning: the reconstruction of experience among schizophrenics, Psychiatry, 55, 266, 10.1080/00332747.1992.11024600 · DOI · Paper page
- Corripio, 2011, Density of striatal D2 receptors in untreated first-episode psychosis: an I(123)-IBZM SPECT study, Eur Neuropsychopharmacol, 21, 861, 10.1016/j.euroneuro.2011.03.004 · DOI
- Delay, 1952, Traitement des états d'excitation et d'agitation par une méthode médicamenteuse dérivée de l'hibernithérapie, Ann Med Psychol (Paris), 110, 267
- Double, 2007, Adolf Meyer's psychobiology and the challenge for biomedicine, Philos Psychiatr Psychol, 14, 331, 10.1353/ppp.0.0139 · doi:10.1353/ppp.0.0139
- Elvevåg, 2010, Conceptual combination and language in schizophrenia, Schizophr Res, 120, 238, 10.1016/j.schres.2010.04.006 · doi:10.1016/j.schres.2010.04.006
- Farde, 1990, D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride, Arch Gen Psychiatry, 47, 213, 10.1001/archpsyc.1990.01810150013003 · DOI · Paper page
- Garrett, 2003, Auditory hallucinations, source monitoring, and the belief that “voices” are real, Schizophr Bull, 29, 445, 10.1093/oxfordjournals.schbul.a007018 · DOI · Paper page
- Giannini, 1984, Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity, J Toxicol Clin Toxicol, 22, 573, 10.3109/15563658408992586 · DOI · Paper page
- Giannini, 2000, Acute ketamine intoxication treated by haloperidol: a preliminary study, Am J Ther, 7, 389, 10.1097/00045391-200007060-00008 · DOI
- Graff-Guerrero, 2009, The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study, Neuropsychopharmacology, 34, 1078, 10.1038/npp.2008.199 · DOI
- Hall, 1995, Effect of clozapine and risperidone on 5-HT2 and D2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study, Eur Neuropsychopharmacol, 5, 19, 10.1016/0924-977X(94)00127-W · DOI
- Howes, 2012, The nature of dopamine dysfunction in schizophrenia and what this means for treatment, Arch Gen Psychiatry, 69, 776, 10.1001/archgenpsychiatry.2012.169 · DOI · Paper page
- Iyo, 2013, Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis, J Clin Psychopharmacol, 33, 398, 10.1097/JCP.0b013e31828ea95c · DOI · Paper page
- Kapur, 2005, Evidence for onset of antipsychotic effects within the first 24hours of treatment, Am J Psychiatry, 162, 939, 10.1176/appi.ajp.162.5.939 · DOI · Paper page
- Kegeles, 2010, Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography, Biol Psychiatry, 68, 634, 10.1016/j.biopsych.2010.05.027 · DOI
- Kimura, 2013, Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis, Schizophr Res, 145, 130, 10.1016/j.schres.2013.01.008 · DOI
- Laruelle, 1999, Increased dopamine transmission in schizophrenia: relationship to illness phases, Biol Psychiatry, 46, 56, 10.1016/S0006-3223(99)00067-0 · DOI · Paper page
- Lieberman, 1987, Provocative tests with psychostimulant drugs in schizophrenia, Psychopharmacology (Berl), 91, 415, 10.1007/BF00216006 · DOI · Paper page
- Madras, 2013, History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia, J Hist Neurosci, 22, 62, 10.1080/0964704X.2012.678199 · DOI
- Maor-Nof, 2013, Neurite pruning and neuronal cell death: spatial regulation of shared destruction programs, Curr Opin Neurobiol, 10.1016/j.conb.2013.06.007 · DOI
- Meyer, 1922, Constructive formulation of schizophrenia, Am J Psychiatry, 78, 355, 10.1176/ajp.78.3.355 · doi:10.1176/ajp.78.3.355
- Miller, 1993, Loss of striatal cholinergic neurons as a basis of tardive and l-dopa-induced dyskinesias, and neuroleptic-induced supersensitivity psychosis, Biol Psychiatry, 34, 713, 10.1016/0006-3223(93)90044-E · DOI
- Pappa, 2009, Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review, Psychol Med, 39, 1065, 10.1017/S0033291708004716 · DOI · Paper page
- Peluso, 2012, Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs, Br J Psychiatry, 200, 387, 10.1192/bjp.bp.111.101485 · DOI · Paper page
- Perreault, 2010, The dopamine D1–D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia, J Biol Chem, 285, 36625, 10.1074/jbc.M110.159954 · DOI · Paper page
- Samaha, 2013, Can antipsychotic treatment contribute to drug addiction in schizophrenia?, Prog Neuropsychopharmacol Biol Psychiatry
- Seeman, 2009, Schizophrenia model of elevated D2High receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2High, Schizophr Res, 109, 191, 10.1016/j.schres.2008.12.024 · DOI
- Seeman, 2012, Comment on “A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” by Kinon, B.J. et al., J Clin Psychopharmacol, 32, 291, 10.1097/JCP.0b013e318248daaa · DOI
- Seeman, 2012, Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans, Synapse, 66, 88, 10.1002/syn.20987 · DOI
- Seeman, 2013, Schizophrenia and dopamine receptors, Eur Neuropsychopharmacol, 23, 999, 10.1016/j.euroneuro.2013.06.005 · DOI
- Seeman, 2013, Are dopamine D2 receptors out of control in psychosis?, Prog Neuropsychopharmacol Biol Psychiatry, 46, 146, 10.1016/j.pnpbp.2013.07.006 · DOI
- Seeman, 2013, Schizophrenia thalamus imaging: low benzamide binding to dopamine D2 receptors suggests fewer D2Short receptors and less presynaptic terminals, Psychiatry Res: Neuroimaging, 10.1016/j.pscychresns.2013.09.013 · DOI
- Seeman, 2013, Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia, Prog Neuropsychopharmacol Biol Psychiatry, 44, 178, 10.1016/j.pnpbp.2013.02.011 · DOI
- Seeman, 1975, Brain receptors for antipsychotic drugs and dopamine: direct binding assays, Proc Natl Acad Sci U S A, 72, 4376, 10.1073/pnas.72.11.4376 · DOI · Paper page
- Seeman, 1987, Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases, Neuropsychopharmacology, 1, 5, 10.1016/0893-133X(87)90004-2 · DOI · Paper page
- Seeman, 2009, Dopamine D2High receptors stimulated by phencyclidines, LSD, salvinorin A, and modafinil, Synapse, 63, 698, 10.1002/syn.20647 · DOI · Paper page
- Talvik, 2003, Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457, Int J Neuropsychopharmacol, 6, 361, 10.1017/S1461145703003699 · DOI · Paper page
- Talvik, 2006, Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography, Psychiatry Res: Neuroimaging, 148, 165, 10.1016/j.pscychresns.2006.05.009 · DOI
- Tuppurainen, 2006, Midbrain dopamine D2/3 receptor binding in schizophrenia, Eur Arch Psychiatry Clin Neurosci, 256, 382, 10.1007/s00406-006-0649-3 · DOI
- Volkow, 2009, Substance use disorders in schizophrenia — clinical implications of comorbidity, Schizophr Bull, 35, 469, 10.1093/schbul/sbp016 · DOI · Paper page
- Wang, 2010, Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization, Mol Brain, 3, 25, 10.1186/1756-6606-3-25 · DOI · Paper page
- Yasuno, 2004, Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia, Am J Psychiatry, 161, 1016, 10.1176/appi.ajp.161.6.1016 · DOI · Paper page
- Yuhas, 2013, Throughout history, defining schizophrenia has remained a challenge (timeline), Sci Am Mind
Cited by
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders
Pinares-Garcia, P., Stratikopoulos, M., Zagato, A., Loke, H., & Lee, J. (2018) · Brain Sciences · doi:10.3390/brainsci8080154 · Cited by 200
The effects of psychosocial stress on dopaminergic function and the acute stress response
Bloomfield, M. A., McCutcheon, R. A., Kempton, M., Freeman, T. P., & Howes, O. (2019) · eLife · doi:10.7554/elife.46797 · Cited by 112
“Yet, despite a blunted dopamine response, this study found the classically described relationship between dopamine release and increase in psychotic symptoms, which may be due to D2 receptor super-sensitivity (Seeman and Seeman, 2014).”
BackgroundDopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia
Suzuki, T., Kanahara, N., Yamanaka, H., Takase, M., Kimura, H., Watanabe, H., & Iyo, M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.02.021 · Cited by 81
Metadata
- Authors
- Seeman, M. V., & Seeman, P.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 48
- Pages
- 155-160
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2048982528
- Cited by
- 81
- References
- 10
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is schizophrenia a dopamine supersensitivity psychotic reaction? https://app.cochat.ai/papers/10.1016/j.pnpbp.2013.10.003
- The paper
- Seeman, M. V., & Seeman, P. (2014). Is schizophrenia a dopamine supersensitivity psychotic reaction? Progress in Neuro-Psychopharmacology and Biological Psychiatry. https://doi.org/10.1016/j.pnpbp.2013.10.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.